A Phase 3 interventional study of NXT007 and Emicizumab in Hemophilia A, sponsored by Hoffmann-La Roche. Recruiting at 63 sites in 22 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hemophilia A by Hoffmann-La Roche — 5 open to participants now, 8 under way, 4 of them phase 3. Hemophilia A · Hoffmann-La Roche.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one has the largest planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 in phase 3, and was the 23rd registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →5 of the 25 studies in Hemophilia A by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Japan
Ages 0–17
Hoffmann-La Roche · Sites in United States
Ages 18+ · Men only
Hoffmann-La Roche · Sites in United States, Argentina, Austria and 15 more countries
Ages 12+
Hoffmann-La Roche · Sites in United States, Canada, Italy and 3 more countries
Ages 2–59 · Men only
By country, each count listing its studies:
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 12 · Phase 4 2
First in 2012; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 360 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 58 across the 20 interventional studies, 66 across the 4 observational. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
2 of the studies in Hemophilia A by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07416526Phase 3Hoffmann-La RocheA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A | 2027-09-23 |
| NCT05181618Hoffmann-La RocheA Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis | 2026-11-19 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will receive NXT007 prophylaxis for the main study treatment period.
Combination Product: NXT007
Participants randomized to this arm will receive emicizumab prophylaxis for the main study treatment period at 3 mg/kg once weekly (QW) for 4 weeks as loading doses, followed by maintenance dosing of either 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W). Loading doses are not required for participants who were taking emicizumab prior to study start.
Drug: Emicizumab
After the main study treatment period, participants in the NXT007 arm will be able to continue with NXT007 dosing, and participants in the Emicizumab arm will be able to switch to NXT007, in the open-label extension period.
Combination Product: NXT007
NXT007 will be administered subcutaneously (SC) using an integrated drug-device combination product.
Also known as: Zemocimig, RO7589655, RG6512
Emicizumab will be administered subcutaneously (SC) using vial and syringe.
Also known as: Hemlibra, RO5534262, RG6013
Annualized Bleed Rate (ABR) for Treated Bleeds Over the Main Study Treatment Period
Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
ABR for All Bleeds Over the Main Study Treatment Period
Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
ABR for Treated Spontaneous Bleeds Over the Main Study Treatment Period
Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
ABR for Treated Joint Bleeds Over the Main Study Treatment Period
Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
Adjusted Mean Treatment Burden Domain Score in Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) Questionnaire - Adult Version at Month 8
Time frame: Month 8
ABR for Treated Target Joint Bleeds Over the Main Study Treatment Period
Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
Percentage of Participants with Zero Treated Bleeds Over the Main Study Treatment Period
Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
Number of Injections and Dose per Bleed of Coagulation Factors or Bypassing Agent Administered to Treat a Bleed Over the Main Study Treatment Period
Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
Annualized Injection Rate of FVIII or Bypassing Agent Over the Main Study Treatment Period
Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
Annualized Consumption Rate of FVIII or Bypassing Agent Over the Main Study Treatment Period
Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
Mean Treatment Burden Domain Score in CATCH Questionnaire - Adolescent Version at Month 8
Time frame: Month 8
Change From Baseline in Preoccupation Domain Score of the CATCH Questionnaire (Adult and Adolescent Versions)
Time frame: At prespecified timepoints from Baseline until Study Completion (approximately 3.5 years)
Change From Baseline in Social Activity Impact Domain Score of the CATCH Questionnaire (Adult and Adolescent Versions)
Time frame: At prespecified timepoints from Baseline until Study Completion (approximately 3.5 years)
Change From Baseline in Recreational Activity Impact Domain Score of the CATCH Questionnaire (Adult and Adolescent Versions)
Time frame: At prespecified timepoints from Baseline until Study Completion (approximately 3.5 years)
Physical Impact Domain Score of the Treatment Administration Satisfaction Questionnaire (TASQ) at Specified Timepoints
Time frame: At prespecified timepoints from Baseline to Month 4
Incidence and Severity of Adverse Events, With Severity Determined According To National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5.0) Grading Scale
Time frame: From Baseline until Study Completion (approximately 3.5 years)
Incidence and Severity of Thromboembolic Events and Thrombotic Microangiopathy
Time frame: From Baseline until Study Completion (approximately 3.5 years)
Incidence and Severity of Injection-Site Reactions
Time frame: From Baseline until Study Completion (approximately 3.5 years)
Incidence of Adverse Events Leading to Discontinuation of Assigned Study Treatment
Time frame: From Baseline until Study Completion (approximately 3.5 years)
Incidence of Severe Hypersensitivity, Anaphylaxis, or Anaphylactoid Reactions
Time frame: From Baseline until Study Completion (approximately 3.5 years)
Plasma Concentration of NXT007
Time frame: At prespecified timepoints from Baseline to Study Completion (approximately 3.5 years)
Percentage of Participants With Anti-Drug Antibodies (ADAs) Against NXT007 at Baseline and During the Study
Time frame: At prespecified timepoints from Baseline to Study Completion (approximately 3.5 years)
Percentage of Participants With Neutralizing ADAs Against NXT007
Time frame: At prespecified timepoints from Baseline to Study Completion (approximately 3.5 years)
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Apr 2026 (actual). Primary completion is estimated for Feb 2028, 22 months after the start.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 22 months is below that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NXT007